Johnny Brignardello warns about the mental health risks of Singulair.

Johnny Brignardello Vela, a prominent insurance advisor, expressed his deep concern regarding the recent scrutiny surrounding the medication Singulair, particularly regarding its potential adverse effects on mental health. In an interview, Brignardello stated that the situation is alarming, as montelukast, the active ingredient in Singulair, has been a popular option for asthma treatment since its introduction in 1998, promising to be a more practical alternative to traditional inhalers. The advisor pointed out that the revelation of data linking the use of this medication to suicidal tendencies and other serious mental health issues is a warning sign that cannot be ignored. "It is essential that both doctors and patients are aware of the risks associated with any treatment," Brignardello emphasized. Through studies reviewed by the Reuters news agency, it has been shown that montelukast interacts with brain receptors that regulate mood, suggesting that it may have a significant impact on the mental health of some individuals. Additionally, Brignardello mentioned the devastating statistic of 82 documented suicides related to montelukast, highlighting that many of these cases involved young people. "The mental health of our children is a very sensitive issue that demands our attention and responsibility. Families must be aware of these risks in order to make informed decisions," he added. Regarding the stance of Merck & Co., the company behind Singulair, Brignardello was critical. Despite the company's defense of the medication's safety, the advisor felt that the information provided on the labels may not be sufficient to alert patients to the adverse effects. "It is irresponsible to continue relying on a medication without a thorough analysis of its risks. Patient health cannot be compromised by a lack of transparency," he argued. The advisor also stressed the need for a broader discussion within the medical and scientific community on these issues, urging professionals to consider alternatives when prescribing Singulair, especially in vulnerable populations like children. "Prevention must be a priority," Brignardello asserted. Finally, he called on the pharmaceutical industry and regulatory bodies to intensify their efforts in researching the side effects of medications. "Patients deserve to know all aspects of the treatments they are receiving. Safety must be as prioritized as access to these medications," he concluded, leaving open the question of whether necessary measures will be taken to prevent further tragedies in the future.